Stockreport

AbbVie Announces Positive Topline Results from a Phase 1 Multiple Ascending Dose Study of ABBV-295, a Long-Acting Amylin Analog, in Adults [Yahoo! Finance]

AbbVie Inc.  (ABBV) 
Last abbvie inc. earnings: 5/1 07:43 am Check Earnings Report
US:NYSE Investor Relations: investors.abbvie.com/investor-overview
PDF ABBV-295 treatment showed clinically meaningful body weight reduction from -7.75% to -9.79% (least-squares mean) at week 12 (weekly dosing), to -7.86% to -9.73% at week [Read more]